Skip to main content

Table 4 Patient characteristics and outcome between those with advanced lung cancer inflammation index ALI score <18 (more inflammation) and those with ALI score > 18 (less inflammation) at the time of diagnosis

From: Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review

Variable ALI < 18 (n = 83) (%) ALI ≥ 18 (n = 90) (%) P = value
Age (median) 56 58 0.26 (a)
Male 57 (69) 59 (65) 0.74 (b)
AA 42 (51) 48 (53) 0.76 (b)
Adenocarcinoma 51 (61) 53 (59) 0.75 (b)
PS 2-4 27 (32) 15 (17) 0.02 (b)
No chemotherapy 41 (49) 18 (20) <0.001 (b)
>2 metastatic sites 48 (58) 32 (35) 0.003 (b)
Response to chemotherapy 15 (18%) 50 (56%) <0.0001(b)
Median PFS 2.4 5.1 <0.001 (c)
Median OS 3.4 8.3 <0.001 (c)
  1. (a) Student t-test, (b) Chi-square test, (c) Log rant test, AA = African American, PS = Performance status, PFS = Progression free survival, OS = Overall survival. Significant results shown in bold.